全球癌症单株抗体市场规模、份额、趋势和成长分析报告（2026-2034年）

预计癌症单株抗体市场将从 2025 年的 1,318.5 亿美元成长到 2034 年的 6,247.9 亿美元，2026 年至 2034 年的复合年增长率为 18.87%。

由于癌症发病率的上升和对标靶治疗需求的日益增长，癌症单株抗体市场正经历显着增长。单株抗体（mAb）是人工合成的蛋白质，旨在特异性靶向癌细胞，与传统化疗相比，它提供了更精准的治疗选择。随着医疗机构和患者寻求更有效、毒性更小的治疗方法方案，对癌症单株抗体的需求预计将会增加，从而推动该市场的强劲成长。目前的治疗方法包括曲妥珠单抗和Rituximab等已上市的单株抗体，以及针对各种癌症类型的新型药物。

此外，单株抗体技术的进步正在推动市场创新。双特异性抗体、抗体药物复合体和免疫查核点抑制剂的研发，透过提高治疗的疗效和特异性，正在革新癌症治疗。这些创新不仅改善了治疗效果，还最大限度地减少了副作用，并提高了患者的整体生活品质。随着单株抗体新应用和联合治疗的研究不断深入，预计随着更多治疗方案的出现，市场将进一步扩张。

此外，对个人化医疗的日益重视正在重塑癌症单株抗体领域。随着医疗服务提供者越来越认识到根据患者的基因和分子特征量身定制治疗方案的重要性，对符合个人化治疗策略的单株抗体（mAb）的需求预计将会增长。这一趋势在伴随诊断领域尤其重要，因为特定的生物标记可以指导选择合适的单株抗体疗法。随着癌症单株抗体市场的不断发展，创新治疗方法组合、对个人化医疗的关注以及持续的研究将在推动未来成长方面发挥关键作用。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

第四章 全球癌症单株抗体市场（按类型划分）

• 市场分析、洞察与预测
• 人源化单株抗体
• 人类
• 嵌合体
• 小鼠来源

第五章 全球癌症单株抗体市场（依应用划分）

• 市场分析、洞察与预测
• 血癌
• 乳癌
• 肺癌
• 黑色素瘤
• 大肠直肠癌
• 肝癌
• 其他的

第六章 全球癌症单株抗体市场（依最终用户划分）

• 市场分析、洞察与预测
• 医院
• 研究所
• 其他的

7. 全球癌症单株抗体市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd
  • Bristol Myers Squibb Co
  • Merck & Co
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Amgen Inc
  • Novartis AG
  • AstraZeneca Plc
  • Eli Lilly And Company
  • AbbVie

The Cancer Monoclonal Antibodies Market size is expected to reach USD 624.79 Billion in 2034 from USD 131.85 Billion (2025) growing at a CAGR of 18.87% during 2026-2034.

The cancer monoclonal antibodies market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Monoclonal antibodies (mAbs) are engineered proteins designed to specifically target cancer cells, offering a more precise treatment option compared to traditional chemotherapy. As healthcare providers and patients seek effective and less toxic treatment alternatives, the demand for cancer monoclonal antibodies is expected to rise, positioning this market for robust expansion. Current therapies include well-established mAbs such as trastuzumab and rituximab, as well as newer agents that target various cancer types.

Moreover, advancements in monoclonal antibody technology are propelling innovation within the market. The development of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors is revolutionizing cancer treatment by enhancing the efficacy and specificity of therapies. These innovations not only improve treatment outcomes but also minimize side effects, thereby improving the overall quality of life for patients. As research continues to explore new applications and combinations of monoclonal antibodies, the market is likely to expand further, driven by the promise of improved therapeutic options.

Additionally, the growing emphasis on personalized medicine is shaping the cancer monoclonal antibodies landscape. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient profiles based on genetic and molecular characteristics, the demand for mAbs that align with personalized treatment strategies is likely to rise. This trend is particularly relevant in the context of companion diagnostics, where specific biomarkers guide the selection of appropriate monoclonal antibody therapies. As the cancer monoclonal antibodies market continues to evolve, the combination of innovative therapies, a focus on personalized care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Humanized
• Human
• Chimeric
• Murine

By Application

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

By End-user

• Hospitals
• Research Institutes
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Bristol Myers Squibb Co, Merck Co, GlaxoSmithKline plc, Johnson Johnson, Amgen Inc, Novartis AG, AstraZeneca plc, Eli Lilly and Company, AbbVie

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER MONOCLONAL ANTIBODIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Bristol Myers Squibb Co
  • 9.2.3 Merck & Co
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 Johnson & Johnson
  • 9.2.6 Amgen Inc
  • 9.2.7 Novartis AG
  • 9.2.8 AstraZeneca Plc
  • 9.2.9 Eli Lilly And Company
  • 9.2.10 AbbVie